Objective To investigate the effect of insulin pump combined with dipeptidyl peptidase-Ⅳ (DPP-Ⅳ) inhibitor on the treatment of newly diagnosed type 2 diabetes mellitus (T2DM).
Methods Totally 51 newly diagnosed patients with T2DM were randomly divided into experimental group (insulin pump combined with DPP-Ⅳ inhibitor) and control group (insulin pump alone). After 15 days of treatment, the clinical effect was compared between two groups.
Results After treatment, the blood sugar related indexes in both groups significantly improved (P < 0.05), and the blood sugar control of the experimental group was significantly better than that of the control group (P < 0.05). The pancreatic β cell function index, area under curve of C-peptide and insulin resistance index in the experimental group were significantly better than those in the control group (P < 0.05). The dosage of insulin, the ratio of patients with blood sugar reaching the standard completely, the time of blood sugar reaching the standard and the increase value of body mass in the experimental group were significantly better than those in the control group (P < 0.01). The incidence rate of hypoglycemia was 8.00% (2/26) in the experimental group and 12.00% (3/25) in the control group, and there was no significant difference between the two groups (P>0.05). During the treatment, no severe hypoglycemic events and liver and kidney function damage occurred in both groups.
Conclusion Insulin pump combined with DPP-Ⅳ inhibitor is effective in the treatment of newly diagnosed T2DM, which can effectively control blood sugar, reduce insulin resistance and weight gain.
DownLoad: